Sample Size Considerations for Pharmacoepidemiology Studies

Pharmacoepidemiology, Fourth Edition

Volumn , Issue , 2007, Pages 29-36

  Strom, Brian L ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

"rule of threes"; Case series sample size calculation; Case control sample size studies; Controls and number of control groups; Minimum sample size in pharmacoepidemiology study; Sample size calculations for cohort studies; Sample size calculations for dichotomous variables

Indexed keywords

EID: 84889364829     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059876.ch3     Document Type: Chapter

References (9)

1. Makuch RW, Johnson MF. Some issues in the design and interpretation of "negative" clinical trials. Arch Intern Med 1986; 146: 986-9.
2. Young MJ, Bresnitz EA, Strom BL. Sample size nomograms for interpreting negative clinical studies. Ann Intern Med 1983; 99: 248-51.
3. Schlesselman JJ. Sample size requirements in cohort and case- control studies of disease. Am J Epidemiol 1974; 99: 381-4.
4. Stolley PD, Strom BL. Sample size calculations for clinical pharmacology studies. Clin Pharmacol Ther 1986; 39: 489-90.
5. Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS. Prazosin: the first dose phenomenon. BMJ 1976; 2: 1293-4.
6. Joint Commission on Prescription Drug Use. Final Report. Washington, DC, 1980.
7. Gifford LM, Aeugle ME, Myerson RM, Tannenbaum PJ. Cimetidine postmarket outpatient surveillance program. JAMA 1980; 243: 1532-5.
8. Haenszel W, Loveland DB, Sirken MG. Lung cancer mortality as related to residence and smoking history. I. White males. J Natl Cancer Inst 1962; 28: 947-1001.
9. Cohen J. Statistical Power Analysis for the Social Sciences. New York: Academic Press, 1977.